Observational outcomes in proliferative diabetic retinopathy patients following treatment with ranibizumab, panretinal laser photocoagulation or combination therapy - The non-interventional second year follow-up to the PRIDE study.
Gabriele E LangAndreas StahlJessica VoegelerClaudia QuieringLaureen ZarembaKatrin LorenzGeorg SpitalSandra LiakopoulosPublished in: Acta ophthalmologica (2021)
Discontinuation of ranibizumab treatment in PDR patients may result in an increase of NV area and VA loss. Tight monitoring of disease activity and continued treatment beyond the first year is needed to maintain disease control.